Dapagliflozin for heart failure

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Apr 2025: Trial registered, NCT06915870

The trials

NCT06915870: Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

State
Completed
Phase
No phase
People
108 taking part
Started
12 Jul 2024
Primary completion
13 Jan 2025
Arms
In group A, patients were prescribed Dapagliflozin 10 mg daily for 12 weeks
Results
None posted
  1. 12 Jul 2024: Trial started
  2. 13 Jan 2025: Trial completed
  3. 8 Apr 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Dapagliflozin component qternmet, Dapagliflozin (DAPA), Dapagliflozin 10 MG, Dapagliflozin 10 mg daily, Qternmet xr component dapagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.